Abstract
Therapeutic angiogenesis, stimulated growth of new vasculature to compensate for tissue ischemia, has been studied in a number of clinical trials in patients with various ischemic vascular diseases. These clinical trials include growth factor protein and gene therapy, as well as cell therapy. However, almost randomized clinical trials using vascular endothelial growth factor and fibroblast growth factor families, delivered as either recombinant protein or gene therapy, have failed to demonstrate improvement in patients with coronary artery or peripheral artery disease until now. However, randomized clinical trials using bone marrow-derived cells demonstrated modest but some significant benefit in patients with myocardial infarction. This report reviews the current status of randomized clinical trials and some non-randomized clinical trials using these therapies, plus related potential problems.
Keywords: VEGF, FGF, bone marrow-derived cell, peripheral arterial disease, myocardial infarction, clinical review
Current Drug Therapy
Title: Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Volume: 4 Issue: 3
Author(s): Shingo Niimi, Mizuho Harashima and Masashi Hyuga
Affiliation:
Keywords: VEGF, FGF, bone marrow-derived cell, peripheral arterial disease, myocardial infarction, clinical review
Abstract: Therapeutic angiogenesis, stimulated growth of new vasculature to compensate for tissue ischemia, has been studied in a number of clinical trials in patients with various ischemic vascular diseases. These clinical trials include growth factor protein and gene therapy, as well as cell therapy. However, almost randomized clinical trials using vascular endothelial growth factor and fibroblast growth factor families, delivered as either recombinant protein or gene therapy, have failed to demonstrate improvement in patients with coronary artery or peripheral artery disease until now. However, randomized clinical trials using bone marrow-derived cells demonstrated modest but some significant benefit in patients with myocardial infarction. This report reviews the current status of randomized clinical trials and some non-randomized clinical trials using these therapies, plus related potential problems.
Export Options
About this article
Cite this article as:
Niimi Shingo, Harashima Mizuho and Hyuga Masashi, Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy, Current Drug Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488509789055027
DOI https://dx.doi.org/10.2174/157488509789055027 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Current Drug Targets Adjunctive Therapies in Severe Pneumonia in Critical Care Patients
Infectious Disorders - Drug Targets Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Editorial: Continuous Positive Airway Pressure: Life-Saving Technology
Current Respiratory Medicine Reviews Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Patient-Specific Modeling and Multi-Scale Blood Simulation for Computational Hemodynamic Study on the Human Cerebrovascular System
Current Pharmaceutical Biotechnology Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Pharmacophore and 3D QSAR Study of TGFβ Inhibitors
Letters in Drug Design & Discovery Tacrolimus Toxicity Reverses the Inhibitory Effects of Renin Angiotensin System Blockade on PAI-1 Expression in Cardiac Tissue
Current Enzyme Inhibition Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Circulating Aminopeptidase Activities in Men and Women with Essential Hypertension
Current Medicinal Chemistry Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design